Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Belka, ClausSubject: search.filters.subject.SBRT

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia
    (BMC, 2022-01-01) Slotman, Berend J.; Clark, Mary Ann; Ozyar, Enis; Kim, Myungsoo; Itami, Jun; Tallet, Agnes; Debus, Juergen; Pfeffer, Raphael; Gentile, PierCarlo; Hama, Yukihiro; Andratschke, Nicolaus; Riou, Olivier; Camilleri, Philip; Belka, Claus; Quivrin, Magali; Kim, BoKyong; Pedersen, Anders; Felter, Mette van Overeem; Kim, Young Il; Kim, Jin Ho; Fuss, Martin; Valentini, Vincenzo
    Background Magnetic resonance-guided radiotherapy (MRgRT) utilization is rapidly expanding, driven by advanced capabilities including better soft tissue imaging, continuous intrafraction target visualization, automatic triggered beam delivery, and the availability of on-table adaptive replanning. Our objective was to describe patterns of 0.35 Tesla (T)-MRgRT utilization in Europe and Asia among early adopters of this novel technology. Methods Anonymized administrative data from all 0.35T-MRgRT treatment systems in Europe and Asia were extracted for patients who completed treatment from 2015 to 2020. Detailed treatment information was analyzed for all MR-linear accelerators (linac) and -cobalt systems. Results From 2015 through the end of 2020, there were 5796 completed treatment courses delivered in 46,389 individual fractions. 23.5\% of fractions were adapted. Ultra-hypofractionated (UHfx) dose schedules (1-5 fractions) were delivered for 63.5\% of courses, with 57.8\% of UHfx fractions adapted on-table. The most commonly treated tumor types were prostate (23.5\%), liver (14.5\%), lung (12.3\%), pancreas (11.2\%), and breast (8.0\%), with increasing compound annual growth rates (CAGRs) in numbers of courses from 2015 through 2020 (pancreas: 157.1\%